Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE

Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021

An award organized annually by the Association of Women Entrepreneurs and Managers of Navarra, (AMEDNA/NEEZE) aim to highlight the development of professional careers of women executives through their daily work in the economic, professional and social spheres of Navarra.

Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE

I am very grateful to have received this award,”, says Elena. “The distinction belongs to the whole team at 3P Biopharmaceuticals because we have it within us, more than 300 people, 65% of whom are also women, who work with passion every day to develop complex medicines for our customers sharing a single purpose to improve lives.

Along with Elena, the Businesswoman of Navarre 2021 has been awarded to Maite Agüeros Bazo, CEO and Founder of InnoUp Farma S.L. and Entrepreneur of Navarre 2021, awarded to Susana Sánchez, CEO and founder of Moa Foodtech. The awards ceremony will take place next Wednesday, 24 November, at the Baluarte in the presence of the President of the Government of Navarra, María Chivite.

Management Award of Navarre 2021

Elena Erroba Esquíroz was born in Pamplona on 7 September 1981 and, at the age of 40, she brings more than 15 years of professional experience in Biotechnology and Biomedicine. She joined 3P Biopharmaceuticals in February 2011, a crucial moment when the company was a small team of 38 employees and looking for a new market positioning and to redefine its business model in which Elena’s participation was crucial.

Just 8 years after her arrival at the company, in 2019, and at the same time as Keensight Capital became the new majority shareholder – a deal in which she was also actively involved – 3P received FDA approval for the manufacture of pharmaceutical substances in the US market. The most recent milestone, in 2021, was the EMA approval for the manufacture of the world’s first and only mumps vaccine for horses.

Elena has provided a global and strategic vision in the development of medicines for both the definition of 3P’s business model and the international customer acquisition strategy, allowing us to expand into markets such as Europe, North America, Australia and Asia,” explains Dámaso Molero, CEO of 3P Biopharmaceuticals.

Today, 3P Biopharmaceuticals employs around 315 people, eight times more than when Elena Erroba first joined the company.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.